BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15234858)

  • 1. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected drug interactions and adverse events with antiretroviral drugs.
    Moyle G; Boffito M
    Lancet; 2004 Jul 3-9; 364(9428):8-10. PubMed ID: 15234836
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir poses risk with didanosine.
    AIDS Patient Care STDS; 2003 Jun; 17(6):309. PubMed ID: 12880494
    [No Abstract]   [Full Text] [Related]  

  • 5. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
    Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
    Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
    Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
    Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
    Callens S; De Schacht C; Huyst V; Colebunders R
    J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
    [No Abstract]   [Full Text] [Related]  

  • 9. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):427-8. PubMed ID: 15097160
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
    Kirian MA; Higginson RT; Fulco PP
    Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 12. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
    TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
    García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
    Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK
    J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should tenofovir ever be used in association with didanosine?
    Diaz RS
    Braz J Infect Dis; 2005 Dec; 9(6):452-3. PubMed ID: 16410938
    [No Abstract]   [Full Text] [Related]  

  • 16. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir and didanosine: a dangerous liaison.
    Waters L; Maitland D; Moyle GJ
    AIDS Read; 2005 Aug; 15(8):403-6, 413. PubMed ID: 16110555
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate (Viread).
    Porche DJ
    J Assoc Nurses AIDS Care; 2002; 13(3):100-2. PubMed ID: 12064015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney damage reported in some tenofovir users.
    TreatmentUpdate; 2003; 15(2):6-7. PubMed ID: 12693362
    [No Abstract]   [Full Text] [Related]  

  • 20. Tenofovir-related nephrotoxicity in HIV-infected patients.
    Barrios A; García-Benayas T; González-Lahoz J; Soriano V
    AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.